Top

American Journal of Clinical Dermatology

Published in:

08-02-2024 | Review Article

Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma

Authors: Alexandra Haugh, Adil I. Daud

Published in: American Journal of Clinical Dermatology | Issue 3/2024

Abstract

There have been many recent advances in melanoma therapy. While 50% of melanomas have a BRAF mutation and are a target for BRAF inhibitors, the remaining 50% are BRAF wild-type. Immune checkpoint inhibitors targeting PD-1, cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and lymphocyte activated gene-3 (Lag-3) are all approved for the treatment of patients with advanced BRAF wild-type melanoma; however, treatment of this patient population following initial immune checkpoint blockade is a current therapeutic challenge given the lack of other efficacious options. Here, we briefly review available US FDA-approved therapies for BRAF wild-type melanoma and focus on developing treatment avenues for this heterogeneous group of patients. We review the basics of genomic features of both BRAF mutant and BRAF wild-type melanoma as well as efforts underway to develop new targeted therapies involving the mitogen-activated protein kinase (MAPK) pathway for patients with BRAF wild-type tumors. We then focus on novel immunotherapies, including developing checkpoint inhibitors and agonists, cytokine therapies, oncolytic viruses and tumor-infiltrating lymphocytes, all of which represent potential therapeutic avenues for patients with BRAF wild-type melanoma who progress on currently approved immune checkpoint inhibitors.

Ribas A, Wolchok JD. Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol. 2013;25(2):291–6. https://doi.org/10.1016/j.coi.2013.02.011.CrossRefPubMedPubMedCentral

Allison JP, Krummel MF. The Yin and Yang of T cell costimulation. Science. 1995;270(5238):932–3. https://doi.org/10.1126/science.270.5238.932.CrossRefPubMed

Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8(5):765–72. https://doi.org/10.1093/intimm/8.5.765.CrossRefPubMed

Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–34. https://doi.org/10.1084/jem.192.7.1027.CrossRefPubMedPubMedCentral

Wolchok JD, Hodi FS, Weber JS, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci. 2013;1291(1):1–13. https://doi.org/10.1111/nyas.12180.CrossRefPubMedPubMedCentral

Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. https://doi.org/10.1056/NEJMoa1003466.CrossRefPubMedPubMedCentral

Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–64. https://doi.org/10.1016/s1470-2045(09)70334-1.CrossRefPubMed

Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–44. https://doi.org/10.1056/NEJMoa1305133.CrossRefPubMedPubMedCentral

Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in Patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004–12. https://doi.org/10.1200/jco.2014.58.3708.CrossRefPubMedPubMedCentral

10.

Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32. https://doi.org/10.1056/NEJMoa1503093.CrossRefPubMed

11.

Larkin J, Minor D, D’Angelo S, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol. 2018;36(4):383–90. https://doi.org/10.1200/jco.2016.71.8023.CrossRefPubMed

12.

Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. https://doi.org/10.1056/NEJMoa1504030.CrossRefPubMedPubMedCentral

13.

Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–56. https://doi.org/10.1056/NEJMoa1709684.CrossRefPubMedPubMedCentral

14.

Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24–34. https://doi.org/10.1056/NEJMoa2109970.CrossRefPubMedPubMedCentral

15.

Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54. https://doi.org/10.1038/nature00766.CrossRefPubMed

16.

Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer. 2016;16(6):345–58. https://doi.org/10.1038/nrc.2016.37.CrossRefPubMed

17.

Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 2014;9:239–71. https://doi.org/10.1146/annurev-pathol-012513-104658.CrossRefPubMedPubMedCentral

18.

Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014;14(7):455–67. https://doi.org/10.1038/nrc3760.CrossRefPubMedPubMedCentral

19.

Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012;30(20):2522–9. https://doi.org/10.1200/jco.2011.41.2452.CrossRefPubMed

20.

Kiuru M, Busam KJ. The NF1 gene in tumor syndromes and melanoma. Lab Investig. 2017;97(2):146–57. https://doi.org/10.1038/labinvest.2016.142.CrossRefPubMed

21.

Rabbie R, Ferguson P, Molina-Aguilar C, Adams DJ, Robles-Espinoza CD. Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities. J Pathol. 2019;247(5):539–51. https://doi.org/10.1002/path.5213.CrossRefPubMedPubMedCentral

22.

Hayward NK, Wilmott JS, Waddell N, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545(7653):175–80. https://doi.org/10.1038/nature22071.CrossRefPubMed

23.

Newell F, Johansson PA, Wilmott JS, et al. Comparative genomics provides etiologic and biological insight into melanoma subtypes. Cancer Discov. 2022;12(12):2856–79. https://doi.org/10.1158/2159-8290.Cd-22-0603.CrossRefPubMedPubMedCentral

24.

Yeh I, Jorgenson E, Shen L, et al. Targeted genomic profiling of acral melanoma. J Natl Cancer Inst. 2019;111(10):1068–77. https://doi.org/10.1093/jnci/djz005.CrossRefPubMedPubMedCentral

25.

Pham DDM, Guhan S, Tsao H. KIT and melanoma: biological insights and clinical implications. Yonsei Med J. 2020;61(7):562–71. https://doi.org/10.3349/ymj.2020.61.7.562.CrossRefPubMed

26.

Yeh I, Bastian BC. Melanoma pathology: new approaches and classification. Br J Dermatol. 2021;185(2):282–93. https://doi.org/10.1111/bjd.20427.CrossRefPubMedPubMedCentral

27.

Moran JMT, Le LP, Nardi V, et al. Identification of fusions with potential clinical significance in melanoma. Mod Pathol. 2022;35(12):1837–47. https://doi.org/10.1038/s41379-022-01138-z.CrossRefPubMed

28.

Yen I, Shanahan F, Lee J, et al. ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. Nature. 2021;594(7863):418–23. https://doi.org/10.1038/s41586-021-03515-1.CrossRefPubMed

29.

de Braud F, Dooms C, Heist RS, et al. Initial evidence for the efficacy of naporafenib in combination with trametinib in NRAS-mutant melanoma: results from the expansion arm of a phase Ib, open-label study. J Clin Oncol. 2023;41(14):2651–60. https://doi.org/10.1200/jco.22.02018.CrossRefPubMed

30.

Lebbe C. LBA40 Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600- or NRAS-mutant melanoma. Ann Oncol. 2022;33(7):S1407.CrossRef

31.

Sullivan RJ, Infante JR, Janku F, et al. First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study. Cancer Discov. 2018;8(2):184–95. https://doi.org/10.1158/2159-8290.Cd-17-1119.CrossRefPubMed

32.

Tarin M, Némati F, Decaudin D, et al. FAK inhibitor-based combinations with MEK or PKC inhibitors trigger synergistic antitumor effects in uveal melanoma. Cancers. 2023. https://doi.org/10.3390/cancers15082280.CrossRefPubMedPubMedCentral

33.

Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev. 2016;45:129–38. https://doi.org/10.1016/j.ctrv.2016.03.002.CrossRefPubMed

34.

Steeb T, Wessely A, Petzold A, et al. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis. Eur J Cancer. 2021;157:348–57. https://doi.org/10.1016/j.ejca.2021.08.015.CrossRefPubMed

35.

Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008;99(5):734–40. https://doi.org/10.1038/sj.bjc.6604482.CrossRefPubMedPubMedCentral

36.

Arance A, de la Cruz-Merino L, Petrella TM, et al. Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination. J Clin Oncol. 2023;41(1):75–85. https://doi.org/10.1200/jco.22.00221.CrossRefPubMed

37.

Algazi AP, Esteve-Puig R, Nosrati A, et al. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma. Pigment Cell Melanoma Res. 2018;31(1):110–4. https://doi.org/10.1111/pcmr.12644.CrossRefPubMed

38.

Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–50. https://doi.org/10.1038/s41591-018-0014-x.CrossRefPubMedPubMedCentral

39.

Iijima N, Iwasaki A. Tissue instruction for migration and retention of TRM cells. Trends Immunol. 2015;36(9):556–64. https://doi.org/10.1016/j.it.2015.07.002.CrossRefPubMedPubMedCentral

40.

Broz ML, Binnewies M, Boldajipour B, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014;26(5):638–52. https://doi.org/10.1016/j.ccell.2014.09.007.CrossRefPubMedPubMedCentral

41.

Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182(2):459–65. https://doi.org/10.1084/jem.182.2.459.CrossRefPubMed

42.

Weber JS, O’Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26(36):5950–6. https://doi.org/10.1200/jco.2008.16.1927.CrossRefPubMed

43.

Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006;18(2):206–13. https://doi.org/10.1016/j.coi.2006.01.011.CrossRefPubMed

44.

Olson DJ, Eroglu Z, Brockstein B, et al. Pembrolizumab plus ipilimumab following anti-PD-1/L1 failure in melanoma. J Clin Oncol. 2021;39(24):2647–55. https://doi.org/10.1200/jco.21.00079.CrossRefPubMedPubMedCentral

45.

Graydon CG, Mohideen S, Fowke KR. LAG3’s enigmatic mechanism of action. Front Immunol. 2020;11: 615317. https://doi.org/10.3389/fimmu.2020.615317.CrossRefPubMed

46.

Ascierto PA, Lipson EJ, Dummer R, et al. Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti-programmed death-1/programmed death ligand 1 therapy: results from the phase I/IIa RELATIVITY-020 trial. J Clin Oncol. 2023;41(15):2724–35. https://doi.org/10.1200/jco.22.02072.CrossRefPubMedPubMedCentral

47.

Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997;3(6):682–5. https://doi.org/10.1038/nm0697-682.CrossRefPubMed

48.

Gauttier V, Judor JP, Le Guen V, Cany J, Ferry N, Conchon S. Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer. Int J Cancer. 2014;135(12):2857–67. https://doi.org/10.1002/ijc.28943.CrossRefPubMed

49.

Shuford WW, Klussman K, Tritchler DD, et al. 4-1BB costimulatory signals preferentially induce CD8⁺ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med. 1997;186(1):47–55. https://doi.org/10.1084/jem.186.1.47.CrossRefPubMedPubMedCentral

50.

Menk AV, Scharping NE, Rivadeneira DB, et al. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J Exp Med. 2018;215(4):1091–100. https://doi.org/10.1084/jem.20171068.CrossRefPubMedPubMedCentral

51.

Kawalekar OU, O’Connor RS, Fraietta JA, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44(2):380–90. https://doi.org/10.1016/j.immuni.2016.01.021.CrossRefPubMed

52.

Segal NH, Logan TF, Hodi FS, et al. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody. Clin Cancer Res. 2017;23(8):1929–36. https://doi.org/10.1158/1078-0432.Ccr-16-1272.CrossRefPubMed

53.

Segal NH, He AR, Doi T, et al. Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in patients with advanced cancer. Clin Cancer Res. 2018;24(8):1816–23. https://doi.org/10.1158/1078-0432.Ccr-17-1922.CrossRefPubMed

54.

Chen S, Lee LF, Fisher TS, et al. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model. Cancer Immunol Res. 2015;3(2):149–60. https://doi.org/10.1158/2326-6066.Cir-14-0118.CrossRefPubMed

55.

Shindo Y, Yoshimura K, Kuramasu A, et al. Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor. Anticancer Res. 2015;35(1):129–36.PubMed

56.

Vonderheide RH. CD40 agonist antibodies in cancer immunotherapy. Annu Rev Med. 2020;71:47–58. https://doi.org/10.1146/annurev-med-062518-045435.CrossRefPubMed

57.

Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020;20(3):173–85. https://doi.org/10.1038/s41577-019-0224-6.CrossRefPubMed

58.

Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207(10):2187–94. https://doi.org/10.1084/jem.20100643.CrossRefPubMedPubMedCentral

59.

Im SJ, Hashimoto M, Gerner MY, et al. Defining CD8⁺ T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537(7620):417–21. https://doi.org/10.1038/nature19330.CrossRefPubMedPubMedCentral

60.

Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276(1):97–111. https://doi.org/10.1111/imr.12520.CrossRefPubMedPubMedCentral

61.

Hamid O, Mehmi I, Dudzisz-Sledz M, Hoyle PE, Wei W, Powderly JD. A phase 1/2 study of retifanlimab (INCMGA00012, anti-PD-1), INCAGN02385 (anti-LAG-3), and INCAGN02390 (anti–TIM-3) combination therapy in patients (Pts) with advanced solid tumors. J Clin Oncol. 2023;41(16 suppl):2599–2599.CrossRef

62.

Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26(6):923–37. https://doi.org/10.1016/j.ccell.2014.10.018.CrossRefPubMed

63.

Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19(7):723–32. https://doi.org/10.1038/s41590-018-0132-0.CrossRefPubMed

64.

Wang Y, Du J, Gao Z, et al. Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. Br J Cancer. 2023;128(7):1196–207. https://doi.org/10.1038/s41416-022-02084-y.CrossRefPubMed

65.

Demerlé C, Gorvel L, Olive D. BTLA-HVEM couple in health and diseases: insights for immunotherapy in lung cancer. Front Oncol. 2021;11: 682007. https://doi.org/10.3389/fonc.2021.682007.CrossRefPubMedPubMedCentral

66.

Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. B7H3 as a promoter of metastasis and promising therapeutic target. Front Oncol. 2018;8:264. https://doi.org/10.3389/fonc.2018.00264.CrossRefPubMedPubMedCentral

67.

Buchan SL, Rogel A, Al-Shamkhani A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood. 2018;131(1):39–48. https://doi.org/10.1182/blood-2017-07-741025.CrossRefPubMed

68.

Amatore F, Gorvel L, Olive D. Role of inducible co-stimulator (ICOS) in cancer immunotherapy. Expert Opin Biol Ther. 2020;20(2):141–50. https://doi.org/10.1080/14712598.2020.1693540.CrossRefPubMed

69.

Zappasodi R, Sirard C, Li Y, et al. Rational design of anti-GITR-based combination immunotherapy. Nat Med. 2019;25(5):759–66. https://doi.org/10.1038/s41591-019-0420-8.CrossRefPubMedPubMedCentral

70.

Gu SS, Zhang W, Wang X, et al. Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade. Cancer Discov. 2021;11(6):1524–41. https://doi.org/10.1158/2159-8290.Cd-20-0812.CrossRefPubMedPubMedCentral

71.

Chen X, Lu Q, Zhou H, et al. A membrane-associated MHC-I inhibitory axis for cancer immune evasion. Cell. 2023;186(18):3903-3920.e21. https://doi.org/10.1016/j.cell.2023.07.016.CrossRefPubMedPubMedCentral

72.

Bentebibel SE, Diab A. Cytokines in the treatment of melanoma. Curr Oncol Rep. 2021;23(7):83. https://doi.org/10.1007/s11912-021-01064-4.CrossRefPubMed

73.

Diab A, Gogas H, Sandhu S, et al. Bempegaldesleukin plus nivolumab in untreated advanced melanoma: the open-label, phase III PIVOT IO 001 trial results. J Clin Oncol. 2023. https://doi.org/10.1200/jco.23.00172.CrossRefPubMedPubMedCentral

74.

Greaney SK, Algazi AP, Tsai KK, et al. Intratumoral plasmid IL12 electroporation therapy in patients with advanced melanoma induces systemic and intratumoral T-cell responses. Cancer Immunol Res. 2020;8(2):246–54. https://doi.org/10.1158/2326-6066.Cir-19-0359.CrossRefPubMed

75.

Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2000;18(8):1614–21. https://doi.org/10.1200/jco.2000.18.8.1614.CrossRefPubMed

76.

Lawson DH, Lee S, Zhao F, et al. Randomized, placebo-controlled, phase III trial of yeast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) versus peptide vaccination versus GM-CSF plus peptide vaccination versus placebo in patients with no evidence of disease after complete surgical resection of locally advanced and/or stage IV melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J Clin Oncol. 2015;33(34):4066–76. https://doi.org/10.1200/jco.2015.62.0500.CrossRefPubMedPubMedCentral

77.

Andtbacka RHI, Collichio F, Harrington KJ, et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer. 2019;7(1):145. https://doi.org/10.1186/s40425-019-0623-z.CrossRefPubMedPubMedCentral

78.

Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109-1119.e10. https://doi.org/10.1016/j.cell.2017.08.027.CrossRefPubMedPubMedCentral

79.

Andtbacka RHI, Curti B, Daniels GA, et al. Clinical responses of oncolytic coxsackievirus A21 (V937) in patients with unresectable melanoma. J Clin Oncol. 2021;39(34):3829–38. https://doi.org/10.1200/jco.20.03246.CrossRefPubMed

80.

Chmielowski B, Milhem MM, Sacco JJ, et al. Initial efficacy and safety of RP1 + nivolumab in patients with anti-PD-1-failed melanoma from the ongoing phase 1/2 IGNYTE study. J Clin Oncol. 2023;41(16 suppl):9509–9509. https://doi.org/10.1200/JCO.2023.41.16_suppl.9509.CrossRef

81.

Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550–7. https://doi.org/10.1158/1078-0432.Ccr-11-0116.CrossRefPubMedPubMedCentral

82.

Ellebaek E, Iversen TZ, Junker N, et al. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med. 2012;10:169. https://doi.org/10.1186/1479-5876-10-169.CrossRefPubMedPubMedCentral

83.

Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol. 2021;39(24):2656–66. https://doi.org/10.1200/jco.21.00612.CrossRefPubMedPubMedCentral

84.

Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022. https://doi.org/10.1136/jitc-2022-005755.CrossRefPubMedPubMedCentral

Title: Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma
Authors: Alexandra Haugh
Adil I. Daud
Publication date: 08-02-2024
Publisher: Springer International Publishing
Published in: American Journal of Clinical Dermatology / Issue 3/2024
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-023-00841-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2024

Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)

Correction to: OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target

Field Cancerization Therapies for the Management of Actinic Keratosis: An Updated Review

Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis

Management of Acne in Pregnancy

Autoimmune, Autoinflammatory Disease and Cutaneous Malignancy Associations with Hidradenitis Suppurativa: A Cross-Sectional Study